Royalty Pharma plc (RPRX) concluded trading on Wednesday at a closing price of $32.59, with 8.03 million shares of worth about $261.76 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.95% during that period and on February 19, 2025 the price saw a loss of about -0.79%. Currently the company’s common shares owned by public are about 445.99M shares, out of which, 372.09M shares are available for trading.
Stock saw a price change of 1.05% in past 5 days and over the past one month there was a price change of 5.98%. Year-to-date (YTD), RPRX shares are showing a performance of 27.75% which increased to 8.52% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.05 but also hit the highest price of $32.89 during that period. The average intraday trading volume for Royalty Pharma plc shares is 3.75 million. The stock is currently trading 2.76% above its 20-day simple moving average (SMA20), while that difference is up 13.84% for SMA50 and it goes to 17.70% higher than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 445.99M outstanding shares and institutions hold larger chunk of about 74.42% of that.
The stock has a current market capitalization of $18.79B and its 3Y-monthly beta is at 0.49. PE ratio of stock for trailing 12 months is 17.00, while it has posted earnings per share of $1.92 in the same period. Its PEG reads 1.33 and has Quick Ratio of 1.44 while making debt-to-equity ratio of 1.10. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 2.13% while standing at 1.94% over the month.
Stock’s fiscal year EPS is expected to rise by 13.79% while it is estimated to increase by 8.28% in next year. EPS is likely to grow at an annualized rate of 12.82% for next 5-years, compared to annual growth of -21.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on June 03, 2024 offering a Neutral rating for the stock and assigned a target price of $28 to it. Coverage by UBS stated Royalty Pharma plc (RPRX) stock as a Buy in their note to investors on June 14, 2022, suggesting a price target of $47 for the stock. On May 13, 2022, Scotiabank Initiated their recommendations, while on April 27, 2022, Goldman Initiated their ratings for the stock with a price target of $56. Stock get an Overweight rating from JP Morgan on April 14, 2022.
